The oral GLP-1 field got its next Phase 3 entrant on August 30, 2026, when Ascletis Pharma dosed the first participant in AURORA — a two-trial, ~4,600-patient global program testing ASC30, a once-daily oral small-molecule GLP-1 receptor agonist, across the US, Europe and Canada. Four weeks earlier the same company disclosed something arguably more interesting: preclinical data on a once-daily oral GLP-1/GIP/amylin fixed-dose combination that drove 15.2% body-weight reduction in non-human primates after seven days of dosing.
Research-context information only. This article reports trial data and what it means for buyers. ASC30 is investigational and not approved by any regulator. Retatrutide is an investigational drug not approved by the FDA; possession or use outside an authorized clinical trial may be illegal in your jurisdiction. This article reports what has been documented, not what should be done. Consult a licensed physician for personal medical decisions.
Both items matter for the same reason: they are attempts to compress a triple-agonist injectable's effect into a pill. Neither is buyable, and neither will be for years. The practical question — the one the headlines never answer — is what the pipeline news changes about the options in front of you today. The honest answer is: nothing yet, and that itself is worth knowing.
What Ascletis Actually Announced
ASC30 is a small molecule, not a peptide. That distinction is the whole point. Injectable GLP-1s like semaglutide and tirzepatide are peptide chains that the gut degrades, which is why they are injected. A small molecule survives oral absorption, so it can be swallowed — the same trick orforglipron pulled off.
The Phase 3 program (AURORA). Two pivotal trials cleared by the FDA:
| Trial | Population | NCT |
|---|---|---|
| AURORA-1 | Obesity/overweight, no type 2 diabetes | NCT07743463 |
| AURORA-2 | Obesity/overweight, with type 2 diabetes | NCT07743450 |
Combined enrolment is roughly 4,600 participants. Both trials test three once-daily maintenance doses — 20 mg, 40 mg and 60 mg — against placebo over 72 weeks, with titration periods of 12, 16 or 20 weeks depending on the target dose. The primary endpoint is percentage change in body weight at week 72. Topline data is expected in Q3 2028, with a US NDA by end of 2028 and a European filing in early 2029.
The Phase 2 data behind it. The doses carried into Phase 3 come from a 13-week US Phase 2 in 125 adults with obesity or overweight plus at least one weight-related comorbidity:
| Once-daily dose | Placebo-adjusted weight loss (13 wks) |
|---|---|
| ASC30 20 mg | 5.4% |
| ASC30 40 mg | 7.0% |
| ASC30 60 mg | 7.7% |
The response was dose-dependent with no plateau at 13 weeks, which is the argument for a 72-week Phase 3. The tolerability claim is the more differentiating one: titrated weekly to target dose, ASC30 produced roughly half the vomiting rate reported for weekly-titrated orforglipron, and all gastrointestinal adverse events were grade 1 or 2, concentrated in the titration window. Ascletis has separately reported that a fast, high-dose titration bought no extra efficacy, so the low-and-slow regimen is what went forward.
The depot version. The same molecule has an ultra-long-acting subcutaneous depot formulation, which posted 6.3% placebo-adjusted weight loss at week 12 and 7.5% at week 16 after three monthly doses, with weight loss maintained for the four months following the final injection and an observed half-life around 75 days. That opens the door to monthly — possibly quarterly — maintenance dosing without a weekly lead-in, a very different convenience profile from anything currently on the market.
The triple combination. On August 3, alongside the Phase 3 initiation, Ascletis released non-human-primate data for ASC30_48_39FDC — a fixed-dose combination of ASC30 (GLP-1 receptor), ASC48 (GIP receptor) and ASC39 (amylin receptor), all small molecules, all in one daily tablet. After seven days of oral dosing it produced up to 15.2% body-weight reduction, described as 120% greater than the GLP-1/amylin dual combination alone. An IND filing is planned for Q4 2026. Ascletis also began a US Phase 1 for ASC36, an amylin receptor peptide agonist, in August.
Seven days in monkeys is not 72 weeks in humans, and the graveyard of obesity candidates is full of spectacular primate data. But the direction is worth noting: the same three-target logic that made retatrutide the highest-efficacy injectable in the class is now being attempted in pill form.
What This Means for You
Start with the part the press release does not say: there is no way to buy ASC30. It is a proprietary small molecule under active patent protection, not a peptide sequence a research vendor can synthesise and vial. Unlike GLP-1 peptides, there is no grey-market route to a small-molecule tablet — the synthesis, formulation and analytics are a different problem entirely. Anything marketed as "ASC30" today is not ASC30.
That leaves the same two legitimate routes that existed last week.
Route 1: The oral pill that already exists
Orforglipron was FDA-approved in April 2026 — the first oral small-molecule GLP-1, with no food or water timing restrictions. It delivered roughly 12-13% weight loss in Phase 3, well above ASC30's 13-week Phase 2 figure, though the two have never been compared head to head and the trial durations are not remotely equivalent. It is a prescription drug available through retail pharmacies and telehealth now. If a daily pill is the requirement, orforglipron is the only approved one.
Route 2: Compounded injectable GLP-1 peptides
For readers who care more about weight-loss magnitude than pill convenience, injectable GLP-1 peptides remain the more heavily trafficked option on this site among readers comparing the two routes. Nothing in the ASC30 news changes vendor pricing, stock or COA status:
- Best Semaglutide Vendors — current pricing on 5mg and 10mg vials
- Best Tirzepatide Vendors — pricing on 10mg, 30mg and 60mg vials
- Best Retatrutide Vendors — the triple agonist with the highest Phase 3 weight-loss numbers to date
- Best Cagrilintide Vendors — the amylin analog ASC39 is chasing in small-molecule form
- All Active Vendor Coupons — current discount codes across recommended vendors
Affiliate disclosure: some vendor links above and below are affiliate links; we may earn a commission if you buy through them.
The framing that actually helps: ASC30 is a 2029-at-the-earliest proposition, and the triple-combination tablet is a 2027 IND. Both are reasons to watch the oral space, not reasons to wait. The decision in front of anyone reading this in 2026 is orforglipron versus an injectable peptide.
